Literature DB >> 15588131

Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease.

T Seeman1, J Dusek, K Vondrák, K Bláhová, E Simková, J Kreisinger, P Dvorák, M Kyncl, Z Hríbal, J Janda.   

Abstract

Impaired glomerular filtration rate (GFR) is a risk factor for the development of hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD). However, markers of tubular function were not tested whether they are linked to hypertension or blood pressure (BP) level. The aim of our study was to investigate the relationship between renal concentrating capacity and BP in children with ADPKD. Fifty-three children (mean age 11.8+/-4.4 years) were investigated. Standardized renal concentrating capacity test was performed after nasal drop application of desmopressin, BP was measured by ambulatory BP monitoring (ABPM). Renal concentrating capacity was decreased in 58 % of children. The prevalence of hypertension was significantly higher in children with decreased renal concentrating capacity (35 %) than in children with normal renal concentrating capacity (5 %) (p<0.05). Significant negative correlations were found between renal concentrating capacity, ambulatory BP and number of renal cysts (r = -0.29 to -0.39, p<0.05 to p<0.01). In conclusion, the concentrating capacity is decreased in about half of the patients and is linked to BP. Decreased renal concentrating capacity should be considered.

Entities:  

Mesh:

Year:  2004        PMID: 15588131

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  24 in total

Review 1.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 2.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

4.  Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Authors:  Ron T Gansevoort; Maatje D A van Gastel; Arlene B Chapman; Jaime D Blais; Frank S Czerwiec; Eiji Higashihara; Jennifer Lee; John Ouyang; Ronald D Perrone; Katrin Stade; Vicente E Torres; Olivier Devuyst
Journal:  Kidney Int       Date:  2019-03-09       Impact factor: 10.612

Review 5.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; Konrad Stepniakowski; Frederic Rahbari-Oskoui
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

6.  Prevalence of Hypertension in Children with Early-Stage ADPKD.

Authors:  Laura Massella; Djalila Mekahli; Dušan Paripović; Larisa Prikhodina; Nathalie Godefroid; Anna Niemirska; Ayşe Ağbaş; Karolina Kalicka; Augustina Jankauskiene; Malgorzata Mizerska-Wasiak; Alberto Caldas Afonso; Rémi Salomon; Georges Deschênes; Gema Ariceta; Z Birsin Özçakar; Ana Teixeira; Ali Duzova; Jérôme Harambat; Tomáš Seeman; Gabriela Hrčková; Adrian Catalin Lungu; Svetlana Papizh; Amira Peco-Antic; Stéphanie De Rechter; Ugo Giordano; Marietta Kirchner; Teresa Lutz; Franz Schaefer; Olivier Devuyst; Elke Wühl; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-19       Impact factor: 8.237

7.  Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Authors:  Debbie Zittema; Else van den Berg; Esther Meijer; Wendy E Boertien; Anneke C Muller Kobold; Casper F M Franssen; Paul E de Jong; Stephan J L Bakker; Gerjan Navis; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

8.  Vasopressin directly regulates cyst growth in polycystic kidney disease.

Authors:  Xiaofang Wang; Yanhong Wu; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

Review 9.  Vasopressin antagonists in polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Semin Nephrol       Date:  2008-05       Impact factor: 5.299

Review 10.  The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.

Authors:  Bharathi V Reddy; Arlene B Chapman
Journal:  Pediatr Nephrol       Date:  2016-03-31       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.